Quantcast
Home > Quotes > KNSA
KNSA

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock (KNSA) Quote & Summary Data

$17.36
*  
0.81
4.46%
Get KNSA Alerts
*Delayed - data as of Mar. 21, 2019  -  Find a broker to begin trading KNSA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    KNSA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
28.5
Today's High / Low
$ 18.2796 / $ 17.10
Share Volume
67,127
50 Day Avg. Daily Volume
180,238
Previous Close
$ 18.17
52 Week High / Low
$ 32.88 / $ 13.04
Market Cap
943,206,298
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
3.29

Intraday Chart

Shares Traded

Share Volume:
67,127
50 Day Avg. Daily Volume:
180,238

Trading Range

The current last sale of $17.36 is 33.13% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18.2796 $ 32.88
 Low: $ 17.10 $ 13.04

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates, across various stages of development, focused on autoinflammatory and autoimmune conditions. We have three clinical­stage product candidates and two pre­clinical­stage product candidates. We follow a disciplined and methodical approach to selectively identify, discover and acquire product candidates with strong biologic rationales or validated mechanisms of action. We believe that our product candidates have the potential to address multiple indications. Our portfolio of product candidates offers multiple development opportunities.  ... More ...  



Risk Grade

Where does KNSA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.05
Open Date:
Mar. 21, 2019
Close Price:
$ 17.36
Close Date:
Mar. 21, 2019


Consensus Recommendation

Analyst Info